In spring 2017, the American Diabetes Association tasked a working group with examining soaring insulin list prices,1 which had nearly tripled between 2002 and 2013.2 Because pharmaceutical spending represents a prime contributor to the escalating costs of diabetes care in the United States,2,3 these increases in insulin pricing warranted analysis.